Citadel Advisors
BLTE

Citadel Advisors’s Belite Bio BLTE Stock Holding History

Citadel Advisors’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.7M Buy
186,168
+184,160
+9,171% +$28.2M ﹤0.01% 2149
2026
Q1 		$320K Sell
2,008
-3,047
-60% -$512K ﹤0.01% 10330
2025
Q4 		$809K Sell
5,055
-5,772
-53% -$684K ﹤0.01% 7893
2025
Q3 		$801K Buy
10,827
+3,371
+45% +$221K ﹤0.01% 8031
2025
Q2 		$430K Buy
7,456
+1,767
+31% +$108K ﹤0.01% 8979
2025
Q1 		$377K Buy
5,689
+478
+9% +$28.8K ﹤0.01% 9090
2024
Q4 		$329K Sell
5,211
-1,249
-19% -$82.3K ﹤0.01% 9459
2024
Q3 		$303K Buy
+6,460
New +$313K ﹤0.01% 9314

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's BLTE Position: Q2 2026 in Review

Citadel Advisors increased its Belite Bio (BLTE) stake by 9,171% in Q2 2026, buying an estimated $28.2M and bringing the position to 186,168 shares worth $28.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

Citadel Advisors first reported a position in BLTE in Q3 2024 and has held it in 8 quarters since. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Citadel Advisors held 186,168 shares of Belite Bio worth $28.7M as of Q2 2026.
  • Citadel Advisors bought 184,160 Belite Bio shares in Q2 2026, an estimated $28.2M.
  • Belite Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2149 holding.
  • Citadel Advisors first reported a position in Belite Bio in Q3 2024 and has held it in 8 quarters since.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.